MASSARO, FULVIO
 Distribuzione geografica
Continente #
NA - Nord America 401
EU - Europa 130
AS - Asia 109
AF - Africa 4
SA - Sud America 1
Totale 645
Nazione #
US - Stati Uniti d'America 395
IT - Italia 55
SG - Singapore 53
SE - Svezia 38
CN - Cina 30
IN - India 21
DE - Germania 9
BG - Bulgaria 4
FI - Finlandia 4
GB - Regno Unito 4
TG - Togo 4
BE - Belgio 3
CA - Canada 3
MX - Messico 3
AT - Austria 2
IE - Irlanda 2
IL - Israele 2
LV - Lettonia 2
PL - Polonia 2
RO - Romania 2
AR - Argentina 1
CH - Svizzera 1
ID - Indonesia 1
KW - Kuwait 1
LT - Lituania 1
PT - Portogallo 1
TR - Turchia 1
Totale 645
Città #
Chandler 59
Fairfield 42
Singapore 41
Ashburn 23
Seattle 22
Wilmington 21
Rome 19
Woodbridge 19
Cambridge 18
Houston 18
Princeton 14
Plano 12
San Paolo di Civitate 12
Beijing 11
Ann Arbor 9
Santa Clara 8
Dearborn 7
Lawrence 7
Millbury 7
Andover 6
Boardman 5
Bremen 4
Lomé 4
Milan 4
Sofia 4
Boston 3
Brussels 3
San Diego 3
Bühl 2
Dallas 2
Dublin 2
Monterotondo 2
New York 2
Norwalk 2
Redmond 2
Reggio Nell'emilia 2
Riga 2
Sirmione 2
Tel Aviv 2
Toronto 2
Atlanta 1
Berlin 1
Bern 1
Bologna 1
Des Moines 1
Falls Church 1
Federal 1
Guangzhou 1
Helsinki 1
Istanbul 1
Jakarta 1
Jinan 1
Kuwait 1
Las Vegas 1
London 1
Mannheim 1
Mexico 1
Mission 1
Monterrey 1
Montreal 1
Nanchang 1
Northampton 1
Putian 1
Redwood City 1
Shijiazhuang 1
Stansted 1
Taiyuan 1
Trento 1
Vaiano Cremasco 1
Zhoushan 1
Totale 459
Nome #
Long-term impact of molecular response fluctuations in chronic myeloid leukaemia patients treated with imatinib. 75
null 61
A Case Of Thrombosis In Congenital Afibrinogenemia: A Physiopathologic And Management Dilemma 56
null 49
A case of thrombosis in congenital afibrinogenemia patient: a physiopathologic and management dilemma 46
null 45
Retrospective Evaluation of Phenotype and Management of A-hypo-dys-Fibrinogenemia in a Cohort of Italian Patients 43
RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF DYSFIBRINOGENEMIA AND HYPODYSFIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS 38
null 37
Investigation of possible correlation between clinical and laboratory phenotype in congenital FXI deficiency: results from a single center 32
RETROSPECTIVE EVALUATION OF PHENOTYPE AND MANAGEMENT OF A-HYPO-FIBRINOGENEMIA IN A COHORT OF ITALIAN PATIENTS 27
Changes in estimated glomerular filtration rate in chronic myeloid leukemia patients treated front line with available TKIs and correlation with cardiovascular events 26
Clinical Results According to Age in Patients with Chronic Myeloid Leukemia Receiving Imatinib Frontline: the Younger, the Later, the Worse? 26
The Eutos long-term survival score accurately predicts the risk of death in chronic myeloid leukaemia patients treated outside of clinical trials 20
null 18
Life-Threatening Autoimmune Hemolytic Anemia and Idhiopatic Thrombocytopenic Purpura. Successful Selective Splenic Artery Embolization 16
Incidence of Clinically Significant (<= 10 g/dL) Late Anemia in Elderly Patients with Newly Diagnosed Chronic Myeloid Leukemia Treated with Imatinib 15
Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma 15
Prognostic factors associated with a stable MR4.5 achievement in chronic myeloid leukemia patients treated with imatinib 13
Clinical results according to age in patients with chronic myeloid leukemia receiving imatinib frontline: The younger, the later, the worse? 11
Ruxolitinib in clinical practice for primary and secondary myelofibrosis: an analysis of safety and efficacy of Gruppo Laziale of Ph-negative MPN. 11
Totale 680
Categoria #
all - tutte 2.402
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 2.402


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202089 0 0 0 0 8 16 20 11 14 9 8 3
2020/202118 3 3 0 0 1 5 0 1 2 1 1 1
2021/202292 1 1 7 3 14 12 0 13 6 7 7 21
2022/2023171 24 39 8 21 19 23 3 13 15 0 6 0
2023/202475 6 12 3 4 6 8 2 1 0 11 17 5
2024/202579 3 32 6 32 6 0 0 0 0 0 0 0
Totale 680